SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rebound is being linked by traders to Morgan Stanley naming it a top pick on AWS growth and AI prospects, as well as AWS making its Trainium chips easier for developers to use. Bulls welcome the move and point to cloud and AI momentum, while skeptics question whether it can hold amid heavy capex and recent volatility.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the case for an FDA resubmission, though approval is still pending. Traders are debating the significance of dizziness reported among treated patients and speculating about a short squeeze amid volatile trading.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported takeover interest from Lundbeck is driving speculation about a potential bid or bidding war and heightened trading activity. Xeris has said it is not for sale, leaving traders divided between treating the chatter as a credible deal catalyst and focusing on Recorlev growth and XP-8121s pipeline prospects.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention ahead of its Q3 report after raising its outlook twice, with traders citing higher royalties from its AI-focused Vertical Power Delivery licensing. Bulls see the pullback as a buying opportunity and expect strong results, while others point to the stocks volatility and selling despite the improved outlook.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third quarter and an upbeat 2027 EBITDA outlook are driving CLFs rally, with bullish traders anticipating short covering. Others warn the outlook depends on steel prices and remain focused on the companys debt, while some see the move as a sell-the-news bounce.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing insider share sales and upcoming lockup releases as added supply pressure alongside concerns about valuation, growth and its OpenAI exposure. Bears warn of further downside, while bulls argue the decline is overdone and are buying the dip; some also attribute weakness to a broader AI and semiconductor-sector retreat.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a persistent selloff and weak solar-sector sentiment, with traders pointing to interest-rate sensitivity, policy and financing concerns, and analyst target cuts. The debate is whether its AI data-center, battery-storage and virtual-power-plant initiativesand perceived high short interestcould offset those pressures; some traders view them as a potential turnaround catalyst, while others remain bearish.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios FDA expansion of Anktiva plus BCG to papillary-only bladder cancer, alongside positive long-term trial data, is the main focus. The share-price decline despite those developments has prompted debate over profit-taking, broader biotech weakness and options activity, while some traders allege manipulation without substantiation.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

RGCs sharp move higher is drawing momentum-trading interest, with traders speculating about a repeat meme-stock or short-squeeze run based on its past spikes and reportedly tight share float. Others warn the move may be a pump-and-dump, citing the companys weak fundamentals and the stocks extreme volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

QXO Plunges 43% Year to Date: How Should Investors Play the Stock?

Can QXO overcome rising debt, integration costs and working capital pressures to unlock acquisition synergies and strengthen its earnings potential?

Can QXO Double EBITDA by 2030 After Its $15B TopBuild Deal?

QXO's $15B TopBuild deal expands its building products footprint as it targets more than doubling EBITDA by 2030, despite margin pressure and integration risks.

Why Did CMCSA, NIO, QXO Stocks Tumble To 52-Week Lows Today? 

Equity

Challenges across telecommunications, electric vehicles and building products weighed on investor sentiment.


Stock Market Today, Oct. 7: QXO Falls 7% on RBC Price-Target Cut to $18

QXO (NYSE:QXO), a tech-enabled roofing and building products distributor, closed at $11.30, down 6.65%. A premarket RBC price-target cut and softer residential roofing demand pressured the shares; investors are watching demand trends and execution on integration. Trading volume r...

Why QXO Sank Today

Key PointsQXO received a 33% price target cut from a Wall Street analyst...

QXO Hits Fresh 52-Week Lows On Soft Residential Roofing Demand

RBC analyst Mike Dahl lowered the firm’s target on QXO to $18 from $27 while maintaining an ‘Outperform’ rating.

QXO Stock Tumbles as RBC Analyst Cuts Target

QXO Inc (NYSE:QXO) shares are plummeting Wednesday after an RBC Capital Markets analyst cut the price target on the stock.read more...

Michael Burry Picks Chip Suppliers Over Micron — But Warns Memory Producers Could Sell Off 'Intensely'

Burry also advised shorting equipment makers Applied Materials and Lam Research at current prices.

'Big Short' Michael Burry Tunes Out AI ‘Woo-Hoos’ — Finds Opportunity In Copper, QXO And 3 More Stocks 

Burry’s indirect AI bet is ERO, saying that data-center construction will intensify copper demand while new mines take 18 years to reach production.

Jim Cramer Recommends Buying This Communication Services Stock, Calling It 'Amazing'

Cramer backs Sphere and Cameco, urges selling AppLovin, criticizes Honeywell and QXO, and sees limited-risk upside in Aflac.read more...

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>Comcast shares fell to a 13-year low of $20.75 after SpaceX announced plans to acquire nationwide wireless spectrum.</li><li>Nio shares hit a yearly low of $3.36 on weak September delivery growth.&nbsp;</li><li>QXO shares hit a two-year low after Truist cut its price target to $15 from $26 on weak housing demand.</li></ul><p>Comcast Corp. (CMCSA), Nio Inc. (NIO) and QXO Inc. (QXO) shares hit new 52-week lows Thursday as SpaceX’s spectrum deal raised competition fears, Nio faced slowing delivery growth, and Truist lowered its QXO price target due to a weak housing market and rising transportation costs.&nbsp;</p><p>Nio and QXO stocks fell more than 3% and 1%, respectively, while Comcast stock pared losses and ended the session 1% higher.&nbsp;</p><h2 class="st-heading-2">SpaceX Spectrum Deal Raises Competition Concerns</h2><p><a href="https://stocktwits.com/symbol/CMCSA">Comcast stock</a> plunged to a thirteen-year low of $20.75 after SpaceX (SPCX) announced an agreement to acquire nationwide 800 MHz spectrum from Grain Management. The proposed transaction covers up to 14 MHz of paired spectrum and could expand Starlink Mobile's ability to connect directly with cellular devices.&nbsp;</p><p>Investors worry the technology could intensify competition for traditional wireless providers and cable operators, including Comcast's Xfinity Mobile business. Comcast also faces continued pressure from customers abandoning traditional pay-TV services and growing broadband competition.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock shifted to ‘neutral’ from ‘bearish’.&nbsp;</p><h2 class="st-heading-2">Nio Faces Slower Delivery Growth</h2><p><a href="https://stocktwits.com/symbol/NIO">Nio stock</a> fell to a yearly low of $3.36 after September vehicle deliveries grew just 7.7% year over year, the company's slowest monthly pace in 2026. Deliveries under its ONVO sub-brand fell 42.5% from August, adding to concerns about demand and the company's ability to achieve its fourth-quarter targets.</p><p>Nio delivered 109,178 vehicles in the third quarter, up 25.4% from last year. However, the weaker September figures overshadowed a proposed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-nio-power-deal-geely-battery-swap-business/cZMSQS7RBfa">partnership</a> with Geely involving Nio Power and battery-swapping infrastructure. Investors remain concerned about profit and cash consumption. Retail sentiment around the stock remained ‘bullish’.&nbsp;</p><h2 class="st-heading-2">QXO Target Cut Highlights Building Market Risks</h2><p><a href="https://stocktwits.com/symbol/QXO">QXO stock</a> fell to a two-year low of $10.77 after Truist analyst Keith Hughes cut his price target from $26 to $15 but kept a ‘Buy’ rating. He expects the housing market to recover slowly through 2027, with weak roofing and wallboard prices and higher fuel-related transportation costs hurting the business.&nbsp;</p><p>QXO, led by Brad Jacobs, is pursuing acquisitions to consolidate the fragmented building-products distribution industry. However, high borrowing costs and subdued housing activity continue to challenge expectations for a strong demand recovery. Retail sentiment around the stock slipped to ‘bullish’ from ‘extremely bullish’ territory the previous day.&nbsp;</p><p>So far this year, CMCSA, NIO and QXO stocks have cratered between&nbsp; 24% and 42%.&nbsp;</p><p>Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pep-stock-looks-to-snap-6-week-losing-streak-goldman-sachs-trims-price-target-but-sees-decade-of-growth-for-pepsi-co/cZD6J0KRBV7">PEP Stock Looks To Snap 6-Week Losing Streak: Goldman Sachs Trims Price Target But Sees ‘Decade Of Growth’ For PepsiCo</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of telecommunications company Comcast Corporation is displayed on a smartphone.

Comcast Corp. (CMCSA), Nio Inc. (NIO) and QXO Inc. (QXO) shares hit new 52-week lows Thursday as SpaceX’s spectrum deal raised competition fears, Nio faced slowing delivery growth, and Truist lowered its QXO price target due to a weak housing market and r

Why Did CMCSA, NIO, QXO Stocks Tumble To 52-Week Lows Today?

Comcast Corp

NIO Inc

SpaceX

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.44
Prev Close	$10.86
Open	$10.97
Dividend Yield	0.00%
50-Day Moving Average	$12.72
Beta	1.56
Avg. Volume	19.1M
PE Ratio	-12.15

52-Week High	$27.61
52-Week Low	$10.17
Market Capitalization	$11.27B
EPS (Annual)	-$0.6334
Price to Book	0.85
Revenue Per Employee	$877,880.42

Feed

News

Sentiment

Earnings

Fundamentals

Info

QXO Fundamentals